Literature DB >> 16627254

Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.

Ho-Young Kang1, Ji-Yeon Hwang, Su-Hyun Kim, Hyun-gyung Goh, Myungshin Kim, Dong-Wook Kim.   

Abstract

To identify a fast and sensitive method for screening for mutations in patients with imatinib- resistant chronic myeloid leukemia (CML), we compared allele specific oligonucleotide- polymerase chain reaction (ASO-PCR) assay with conventional direct sequencing. Among the 68 imatinib resistant CML patients studied, 18 amino acid substitutions were detected in 44 patients by two assays. The sensitivity of ASO-PCR was superior to that of direct sequencing as it could detect one mutant allele in 100 approximately 100,000 wild type sequences. The fastness, simplicity, and sensitivity of ASO-PCR assays will be useful for routine monitoring of mutations, especially for frequently identified mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627254

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

1.  Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.

Authors:  Betül Koçkan; Tayfur Toptaş; Işik Atagündüz; Ayşe Tülin Tuğlular; Ayşe Özer; Mustafa Akkiprik
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.

Authors:  Simona Soverini; Antonella Vitale; Angela Poerio; Alessandra Gnani; Sabrina Colarossi; Ilaria Iacobucci; Giuseppe Cimino; Loredana Elia; Annalisa Lonetti; Marco Vignetti; Stefania Paolini; Giovanna Meloni; Valeria di Maio; Cristina Papayannidis; Marilina Amabile; Anna Guarini; Michele Baccarani; Giovanni Martinelli; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

3.  Monitoring response and resistance to treatment in chronic myeloid leukemia.

Authors:  S Assouline; J H Lipton
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

Review 4.  Chronic myeloid leukemia in Asia.

Authors:  Wing Y Au; Priscilla B Caguioa; Charles Chuah; Szu Chun Hsu; Saengsuree Jootar; Dong-Wook Kim; Il-Young Kweon; William M O'Neil; Tapan K Saikia; Jianxiang Wang
Journal:  Int J Hematol       Date:  2008-12-20       Impact factor: 2.490

5.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.

Authors:  Chika Kawajiri; Hiroaki Tanaka; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Toshiyuki Takagi; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2014-02-15       Impact factor: 2.490

6.  Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.

Authors:  Daniel N Egan; Lan Beppu; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-06       Impact factor: 5.742

7.  A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.

Authors:  Wanwisa Wongboonma; Wanna Thongnoppakhun; Chirayu U Auewarakul
Journal:  J Hematol Oncol       Date:  2011-02-08       Impact factor: 17.388

8.  Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Authors:  Zafar Iqbal; Aamer Aleem; Mudassar Iqbal; Mubashar Iqbal Naqvi; Ammara Gill; Abid Sohail Taj; Abdul Qayyum; Najeeb ur-Rehman; Ahmad Mukhtar Khalid; Ijaz Hussain Shah; Muhammad Khalid; Riazul Haq; Mahwish Khan; Shahid Mahmood Baig; Abid Jamil; Muhammad Naeem Abbas; Muhammad Absar; Amer Mahmood; Mahmood Rasool; Tanveer Akhtar
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

9.  Predictive Value of Pretreatment BCR-ABL(IS) Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic Myeloid Leukemia (CPCML).

Authors:  Wafaa H El-Metnawy; Mervat M Mattar; Yasser H El-Nahass; Mohamed A Samra; Hala M Abdelhamid; Raafat M Abdlfattah; Ahmad R Hamed
Journal:  Int J Biomed Sci       Date:  2013-03

10.  Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.

Authors:  Hossam K Mahmoud; Yasser El Nahas; Mohamad Abdel Moaty; Raafat Abdel Fattah; Mohamad El Emary; Wafaa El Metnawy
Journal:  Int J Biomed Sci       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.